Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab’

Sir,

We would like to thank Bibeau et al (2013) for their constructive comment on our article. We acknowledge that the question raised is of crucial interest and, as the evaluation of infarct-like necrosis (ILN) was not planned in our analyses, we went back to our samples in order to investigate it.

We adopted the definition of ILN previously proposed (Chang et al, 2012) and we found 24 (37%) out of 65 patients showing ILN, characterised by large confluent areas of eosinophilic cytoplasmic remnants, located centrally within a lesion and surrounded by a rim of fibrosis with foamy macrophages (Figure 1). Infarct-like necrosis was observed in 1 (5%) out of 28 patients in the control group, in 4 (27%) out of 18 in the chemotherapy group and in 19 (83%) out of 24 in the bevacizumab group (P<0.0001). The ‘bevacizumab-related effect’ previously described was also confirmed in our study (bevacizumab group vs chemotherapy group, P=0.0009; Table 1).

Figure 1
figure1

Examples of usual necrosis (A) and infarct-like necrosis (B).

Table 1 Frequency of infarct-like necrosis in colorectal liver metastases according to treatment

In our samples, patients showing a pathologic response according to the classification proposed by Blazer et al (2008) were more likely to present ILN in comparison to patients showing no pathologic response: ILN was present in 71% of patients showing tumour regression grade (TRG) 1-2-3 vs 29% of patients with TRG 4–5 (P=0.0008). These data strengthen the observation that ILN should be regarded as a particular feature of pathologic response induced by preoperative treatments.

Exploratory outcome analyses showed no differences in terms of progression-free survival according to the presence of ILN both among all treated patients (HR=0.59, 95% CI:0.25–1.36; P=0.21) and in the bevacizumab group (HR=0.42, 95% CI:0.06–1.77; P=0.19). Nevertheless, such analyses in our cohort are affected by the relatively small sample size.

In conclusion, we definitely agree with the proposal from Bibeau et al (2013) to include the evaluation of ILN in future studies assessing pathologic response of colorectal liver metastases to preoperative treatments.

References

  1. Bibeau F, Gil H, Castan F, Boissière-Michot F (2013) Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab’. Br J Cancer 109 (12): 3129–3130.

    Article  Google Scholar 

  2. Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26: 5344–5351.

    Article  Google Scholar 

  3. Chang HH, Leeper WR, Chan G, Quan D, Driman DK (2012) Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 36: 570–576.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to F Loupakis.

Rights and permissions

This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Cite this article

Schirripa, M., Loupakis, F., Pollina, L. et al. Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab’. Br J Cancer 109, 3129–3130 (2013). https://doi.org/10.1038/bjc.2013.652

Download citation

Further reading

Search

Quick links